Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $51.45 USD
Change Today +0.16 / 0.31%
Volume 902.2K
As of 8:04 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

54, Rue La Boétie

Paris, 75008

France

Phone: 33 1 53 77 40 00

Fax: 33 1 53 77 42 96

ailable in 48 markets worldwide. Outside the United States, Myozyme is marketed for patients with both infantile and late onset disease. Myozyme and Lumizyme are administered by intravenous infusion. Both products are a recombinant form of the same human enzyme. Fabrazyme: Fabrazyme (agalsidase beta) is an enzyme replacement therapy used to treat Fabry disease, an inherited, progressive and potentially life threatening LSD. Fabrazyme is administered by intravenous infusion. Fabrazyme is available in approximately 40 countries worldwide. Aldurazyme: Aldurazyme (laronidase) is an enzyme replacement therapy used to treat Mucopolysaccaridosis Type I. The principal markets for Aldurazyme are the United States, Europe, and Latin America. MS Aubagio (teriflunomide), a small molecule immunomodulatory agent with anti-inflammatory properties, reversibly inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme involved in de novo pyrimidine synthesis. The exact mechanism by which teriflunomide exerts its therapeutic effect in MS is unknown but might involve a reduction in various activated lymphocytes in the central nervous system. Aubagio is the oral MS therapy to slow the progression of disability in two Phase III trials (TEMSO and TOWER) and is the only oral therapy shown to prevent or delay a second clinical attack in patients who have experienced initial neurological symptoms suggestive of MS (TOPIC). Aubagio was approved in the United States in 2013 and is approved in approximately 50 countries worldwide, including the European Union and Brazil, with additional marketing applications under review by regulatory authorities globally. Lemtrada (alemtuzumab) is a humanized monoclonal antibody targeting CD52 antigen. Alemtuzumab is developed to treat patients with relapsing forms of MS. In 2013, Lemtrada was granted marketing authorization in the European Union for treatment of adult patients with relapsing forms of MS with active disease defined by clinical or imaging features. Since then, Lemtrada has been approved by regulatory authorities in various countries in the world, including Brazil. In 2014, the FDA approved Lemtrada for the treatment of patients with relapsing forms of MS. Lemtrada is available in the U.S. through a program called the LEMTRADA Risk Evaluation and Mitigation Strategy Program. Lemtrada is approved in approximately 40 countries Additional marketing applications for Lemtrada are under review by regulatory agencies around the world. Oncology The company has a portfolio of 10 marketed products in Oncology, and diversified its presence beyond chemotherapy (Taxotere, Jevtana, and Eloxatin) with Thymoglobulin and Mozobil and with an angiogenesis inhibitor, Zaltrap, launched in 2012 in the United States and in 2013 in the European Union. Jevtana: Jevtana (cabazitaxel), a cytotoxic agent, is a semisynthetic taxane promoting tubulin assembly and stabilizing microtubules, approved in combination with prednisone for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen. In the United States, Jevtana therapy is covered by Centers for Medicare and Medicaid Services, and by majority of the private insurance companies that pay for oncology care. In 2014, the Japanese Health Authority (PMDA) granted marketing authorization for Jevtana, which is approved in approximately 80 countries. The company has initiated a development program with Jevtana. Two post-marketing requirement phase III studies are ongoing in first- and second-line chemotherapy treatment of metastatic castration resistant prostate cancer patients. The clinical program is also evaluating Jevtana in pediatric patients with brain cancer (phase I/II ongoing). The major countries contributing to sales of Jevtana were the United States, France, Germany, Italy, and the U.K. in 2014. Taxotere: Taxotere (docetaxel), a taxoid class derivative, inhibits cancer cell division by essentially ‘freezing’ the cell's internal skeleton, which includes microtubules. Taxotere promotes their assembly and blocks their disassembly, thereby preventing various can

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNY:US $51.45 USD +0.16

SNY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $162.11 USD +1.75
Bayer AG €130.46 EUR +1.45
Gilead Sciences Inc $105.66 USD +0.65
GlaxoSmithKline PLC 1,512 GBp -3.00
Medtronic PLC $75.90 USD +0.30
View Industry Companies
 

Industry Analysis

SNY

Industry Average

Valuation SNY Industry Range
Price/Earnings 29.2x
Price/Sales 3.6x
Price/Book 2.2x
Price/Cash Flow 18.6x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI-ADR, please visit www.sanofi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.